CN102727460A - 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 - Google Patents
一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 Download PDFInfo
- Publication number
- CN102727460A CN102727460A CN2012102168205A CN201210216820A CN102727460A CN 102727460 A CN102727460 A CN 102727460A CN 2012102168205 A CN2012102168205 A CN 2012102168205A CN 201210216820 A CN201210216820 A CN 201210216820A CN 102727460 A CN102727460 A CN 102727460A
- Authority
- CN
- China
- Prior art keywords
- felodipine
- slow
- slow releasing
- label
- releasing tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 title claims abstract description 32
- 229960003580 felodipine Drugs 0.000 title claims abstract description 32
- 150000003839 salts Chemical class 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000010410 layer Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000011248 coating agent Substances 0.000 claims abstract description 42
- 238000000576 coating method Methods 0.000 claims abstract description 42
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical class COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000011230 binding agent Substances 0.000 claims abstract description 13
- 239000011247 coating layer Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000007888 film coating Substances 0.000 claims abstract description 3
- 238000009501 film coating Methods 0.000 claims abstract description 3
- 238000013268 sustained release Methods 0.000 claims description 30
- 239000012730 sustained-release form Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 239000008213 purified water Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- -1 hydroxypropyl Chemical group 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 238000007664 blowing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 229960002237 metoprolol Drugs 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000003361 porogen Substances 0.000 claims description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- ZBOQQGAVXCUYJM-UHFFFAOYSA-N butanedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 ZBOQQGAVXCUYJM-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims description 3
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims description 3
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims description 3
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000011978 dissolution method Methods 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
对照制剂 | 参比制剂 | f2 | 相似性判断 |
LOGIMAX | 实施例1样品 | 86 | 相似 |
LOGIMAX | 实施例2样品 | 92 | 相似 |
LOGIMAX | 实施例3样品 | 88 | 相似 |
LOGIMAX | 实施例4样品 | 90 | 相似 |
对照制剂 | 参比制剂 | f2 | 相似性判断 |
LOGIMAX | 实施例1样品 | 83 | 相似 |
LOGIMAX | 实施例2样品 | 78 | 相似 |
LOGIMAX | 实施例3样品 | 81 | 相似 |
LOGIMAX | 实施例4样品 | 86 | 相似 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210216820.5A CN102727460B (zh) | 2012-06-28 | 2012-06-28 | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210216820.5A CN102727460B (zh) | 2012-06-28 | 2012-06-28 | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102727460A true CN102727460A (zh) | 2012-10-17 |
CN102727460B CN102727460B (zh) | 2015-04-15 |
Family
ID=46984233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210216820.5A Active CN102727460B (zh) | 2012-06-28 | 2012-06-28 | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102727460B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104997750A (zh) * | 2015-07-30 | 2015-10-28 | 杭州康恩贝制药有限公司 | 一种非洛地平缓释片及其制备方法 |
CN106309399A (zh) * | 2015-06-29 | 2017-01-11 | 深圳翰宇药业股份有限公司 | 一种微丸型缓释片及其制备方法 |
CN107153100A (zh) * | 2017-03-27 | 2017-09-12 | 广西厚德大健康产业股份有限公司 | 非洛地平琥珀酸美托洛尔缓释片中杂质的质量控制方法 |
CN108014342A (zh) * | 2016-11-04 | 2018-05-11 | 广州共禾医药科技有限公司 | 一种纤维素醚缓控释制剂质量分析供试品溶液的制备方法 |
CN112691086A (zh) * | 2019-10-22 | 2021-04-23 | 翰宇药业(武汉)有限公司 | 微孔型琥珀酸美托洛尔缓释片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188423A (zh) * | 2010-03-10 | 2011-09-21 | 北京红太阳药业有限公司 | 酒石酸美托洛尔和非洛地平缓释双层片及其制备方法 |
-
2012
- 2012-06-28 CN CN201210216820.5A patent/CN102727460B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188423A (zh) * | 2010-03-10 | 2011-09-21 | 北京红太阳药业有限公司 | 酒石酸美托洛尔和非洛地平缓释双层片及其制备方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106309399A (zh) * | 2015-06-29 | 2017-01-11 | 深圳翰宇药业股份有限公司 | 一种微丸型缓释片及其制备方法 |
CN106309399B (zh) * | 2015-06-29 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种微丸型缓释片及其制备方法 |
CN104997750A (zh) * | 2015-07-30 | 2015-10-28 | 杭州康恩贝制药有限公司 | 一种非洛地平缓释片及其制备方法 |
CN104997750B (zh) * | 2015-07-30 | 2018-03-20 | 杭州康恩贝制药有限公司 | 一种非洛地平缓释片及其制备方法 |
CN108014342A (zh) * | 2016-11-04 | 2018-05-11 | 广州共禾医药科技有限公司 | 一种纤维素醚缓控释制剂质量分析供试品溶液的制备方法 |
CN107153100A (zh) * | 2017-03-27 | 2017-09-12 | 广西厚德大健康产业股份有限公司 | 非洛地平琥珀酸美托洛尔缓释片中杂质的质量控制方法 |
CN107153100B (zh) * | 2017-03-27 | 2019-08-06 | 广西厚德大健康产业股份有限公司 | 非洛地平琥珀酸美托洛尔缓释片中杂质的质量控制方法 |
CN112691086A (zh) * | 2019-10-22 | 2021-04-23 | 翰宇药业(武汉)有限公司 | 微孔型琥珀酸美托洛尔缓释片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102727460B (zh) | 2015-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019268052B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
US4806361A (en) | Medicaments in sustained release unit dose form | |
KR101774676B1 (ko) | 히드로모르폰 및 날록손을 포함하는 제약 조성물 | |
IE48891B1 (en) | A pharmaceutical preparation comprising a cardiac glycoside with a polymer coating,and a process for preparation thereof | |
CN106389381A (zh) | 金刚烷胺组合物及其使用方法 | |
CN102727460B (zh) | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 | |
CN113018273A (zh) | 一种固体制剂及其制备方法和用途 | |
CN104173312A (zh) | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CN103550183B (zh) | 一种盐酸曲美他嗪渗透泵控释片及其制备方法 | |
CN109646417B (zh) | 一种曲美他嗪缓释片及其制备方法 | |
CN101627976A (zh) | 非洛地平缓释制剂及其制备方法 | |
CN104274419A (zh) | 一种以山嵛酸甘油酯为骨架材料的盐酸曲美他嗪缓释片及其制备方法 | |
CN102600451A (zh) | 一种非洛地平雷米普利复方缓释制剂及其制备方法 | |
CN105616358B (zh) | 一种曲美他嗪缓释微丸组合物及其制备方法 | |
CN109330995B (zh) | 一种包载短效降糖药的微丸及其制备方法 | |
CN101756981B (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
CN105616370A (zh) | 一种雷诺嗪缓释片药物组合物及其制备方法 | |
JP2020523290A (ja) | 遅延持続放出医薬組成物 | |
CN101843892B (zh) | 包括依那普利速释部分和非洛地平缓释部分的药物组合物制剂 | |
CN104220064A (zh) | 一种含辛弗林和托吡酯的联合产品 | |
CN114340614B (zh) | 一种奥司他韦制剂 | |
EP4378456A1 (en) | Controlled-release oral preparation and preparation method therefor | |
TW201609196A (zh) | 控制釋放製劑及其製備方法 | |
WO2023093640A1 (zh) | 一种达罗他胺药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Li Li Document name: Notification of Passing Examination on Formalities |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: The 250101 Ji'nan Road, Shandong province hi tech Development Zone, No. 322 room 501-506 Applicant after: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT CO.,LTD. Address before: The 250101 Ji'nan Road, Shandong province hi tech Development Zone, No. 322 room 501-506 Applicant before: SHANDONG ARURA PHARMACEUTICAL RESEARCH & DEVELOPMENT Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG ARURA PHARMACEUTICAL RESEARCH + DEVELOPMENT CO., LTD. TO: SHANDONG JINHE DRUG RESEARCH AND DEVELOPMENT CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 250101 Shandong Province Jinan Hi-tech Zone Comprehensive Bonded Zone No. 1 North Section of Gangxing No. 3 Road Jinan Yaogu R&D Platform Area No. 3 Floor 8001 Patentee after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Address before: 250101 room 501-506, Shun Feng Road, Ji'nan hi tech Zone, Shandong, 501-506 Patentee before: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT CO.,LTD. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190130 Address after: No. 27, mountain Dana Road, Ji'nan City, Shandong, Shandong Co-patentee after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Patentee after: SHANDONG University Address before: 250101 Shandong Province Jinan Hi-tech Zone Comprehensive Bonded Zone No. 1 North Section of Gangxing No. 3 Road Jinan Yaogu R&D Platform Area No. 3 Floor 8001 Patentee before: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. |
|
TR01 | Transfer of patent right |